High Dose Chemotherapy and Hematopoietic Progenitor Cell Transplantation for Breast Cancer

References

• Pedrazzoli P, Siena S. Clinical results in 2001 show high dose therapy and hematopoietic progenitor cell trans-plantation as a therapeutic option for breast cancer. Haematologica 2001; 86: 900–7.
   PubMed Web of Science ®Google Scholar
• Hortobagyi G. High dose chemotherapy in the era of targeted therapies. J Clin Oncol 2004; 10: 1200.
   Google Scholar
• Schmitz N, Linch DC, Dreger P, et al. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell trans-plantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–7.
   PubMed Web of Science ®Google Scholar
• Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell trans-plantation for cancer therapy. J Clin Oncol. 2000; 18: 1360-77.
   Google Scholar
• Gianni AM, Siena S, Bregni M, et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol 1997; 15: 2312-21.
   Google Scholar
• Antman KH, Rowlings PA, Vaughn WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870–1879.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without high-dose chemothera-py and autologous stem-cell transplantation in high-risk breast cancer N Engl J Med 2003; 349: 17–26.
   Google Scholar
• Zander AR, Kroger N, Schmoor C, et al. High dose chemotherapy with autologous hematopoietic stem-cell sup-port versus standard dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol 2004; 10.1200.
   Google Scholar
• Rodenhuis S, Bontenbal M, Beex L, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for highrisk breast cancer. N Engl J Med 2003; 349: 7–16.
   PubMed Web of Science ®Google Scholar
• Elfenbein GJ. Stem-cell transplantation for high-risk breast cancer. N Engl J Med 2003; 349: 80–82.
   PubMed Web of Science ®Google Scholar
• Kowak AK, Wilken NRC, Sockler MR et al. Systematic review of taxane-containing versus non-taxane-containing regi-mens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 2004; 5: 372–380.
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophos-phamide) vs FAC (5-fluorouracil, doxorubicin, cyclophos-phamide) in the adjuvant treatment of node positive breast cancer patients: interim analysis of the BCIRC 001 study. Proc Am Soc Clin Oncol 2002; 21, 36a.
   Google Scholar
• Cagnoni P, Nieto Y, Shpall E, et al. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol 1998; 16: 1661–8.
   PubMed Web of Science ®Google Scholar
• Adkins D, Brown R, Trinkaus K, et al. Outcomes of high-dose chemotherapy and autologous stem-cell transplanta-tion in stage IIIB inflammatory breast cancer. J Clin Oncol 1999; 17: 2006–14.
   PubMed Web of Science ®Google Scholar
• Arun B, Slack R, Gehan E, et al. Survival after autolo-gous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer 1999; 85: 93–9.
   PubMed Web of Science ®Google Scholar
• Eder J, Antman K, Peters W, et al. High-dose combi-nation alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 1986; 4: 1592–7.
   PubMed Web of Science ®Google Scholar
• Peters WP, Shpall EJ, Jones RB et al. High-dose com-bination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368–1376.
   PubMed Web of Science ®Google Scholar
• Peters WP, Dansey RD, Klein JL, Baynes RD. High-dose chemotherapy and peripheral blood progenitor cell trans-plantation in the treatment of breast cancer. Oncologist 2000; 5: 1–13.
   PubMedGoogle Scholar
• Nieto Y. The verdict is not in yet. Analysis of the ran-domized trials of high-dose chemotherapy for breast cancer. Haematologica 2003; 88: 201–11.
   Google Scholar
• Berry DA, Broadwater G, Klein JP, et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of cancer and leukemia group B trials with data from the autologous blood and marrow transplant registry. J Clin Oncol 2002; 20: 743–50.
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P, Ferrante P, Kulekci A et al. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999. Bone Marrow Transplant 2003; 32: 489–494.
   Google Scholar
• Antman KH. Dose intensive therapy in breast cancer. In: Armitage JO, Antman KH, eds. High Dose Cancer Therapy, Pharmacology, Hematopoietins, Stem Cells. Baltimore: Williams and Wilkins, 1992: 701–718.
   Google Scholar
• Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14, 2197–2205.
   PubMed Web of Science ®Google Scholar
• Crump NI, Gluck S, Stewart D et al. A randomized trial of High-Dose Chemotherapy (HDC) with Autologous Peripheral Blood Stem Cell Support (ASCT) compared to standard therapy in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) Clinical Trials Group Study. Proceedings ASCO 2001; 20: abstr. 82.
   Google Scholar
• Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell trans-plantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 2000; 342: 1069–76.
   Google Scholar
• Rowlings PA, Williams SF, Antman KH et al. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA 1999; 282: 1335–43.
   PubMed Web of Science ®Google Scholar
• Nieto Y, Nawaz S, Jones RB et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for Stage IV oligometastatic breast cancer. J Clin Oncol 2002; 20: 707–18.
   PubMed Web of Science ®Google Scholar
• Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expres-sion and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260–6.
   PubMed Web of Science ®Google Scholar